By developing a U.S. payer budget impact model and associated manuscript for Thermo Fisher’s Molecular Microscope® MMDx®-Kidney (a microarray with machine learning for kidney biopsy interpretation), Veranex supported Thermo Fisher’s efforts to communicate the test’s value for evaluating kidney transplant rejection and to facilitate commercial payer acceptance of the test.
